Enzalutamide (Enza), a second-generation androgen receptor (AR) inhibitor via disrupting the translocation of the AR from the cytoplasm into the nucleus and impairing binding of the AR to the transcriptional complex, is approved by FDA to treat PCa patients with different stages of the disease, including castration-resistance prostate cancer (CRPC) (4, 5). Here, AR is linked to posterior cortical atrophy.